{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:42:41Z","timestamp":1793572961122,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":295,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.101026","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T05:22:28Z","timestamp":1761369748000},"page":"101026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6859-3461","authenticated-orcid":false,"given":"Kevin M.","family":"Levine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie F.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted A.","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Voutsinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Tratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Santana-Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice H.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina S.","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctarc.2025.101026_bib0001","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"10.1016\/j.ctarc.2025.101026_bib0002","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1200\/JCO-24-02133","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2024.2","volume":"42","author":"Bazhenova","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101026_bib0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101026_bib0004","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101026_bib0005","first-page":"270","article-title":"Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI","volume":"11","author":"Xia","year":"2014","journal-title":"Cancer Biol. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2025.101026_bib0006","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cllc.2014.07.002","article-title":"Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors","volume":"15","author":"Landi","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2025.101026_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2016.06.008","article-title":"Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer","volume":"99","author":"Cappuzzo","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2025.101026_bib0008","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2016.12.002","article-title":"Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study","volume":"104","author":"Chang","year":"2017","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2025.101026_bib0009","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/COC.0000000000000538","volume":"42","author":"Song","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2025.101026_bib0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/jpm14070752","article-title":"EGFR-tyrosine kinase inhibitor retreatment in non-small-cell lung cancer patients previously exposed to EGFR-TKI: a systematic review and meta-analysis","volume":"14","author":"Michelon","year":"2024","journal-title":"J. Pers. Med."},{"issue":"7","key":"10.1016\/j.ctarc.2025.101026_bib0011","doi-asserted-by":"crossref","first-page":"8413","DOI":"10.21037\/apm-20-2369","article-title":"Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report","volume":"10","author":"Han","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.ctarc.2025.101026_bib0012","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.lungcan.2019.02.021","article-title":"Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer","volume":"132","author":"Ichihara","year":"2019","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101026_bib0013","doi-asserted-by":"crossref","first-page":"816","DOI":"10.21037\/jtd-22-98","article-title":"Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)","volume":"14","author":"Metro","year":"2022","journal-title":"J. Thorac. Dis."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101026_bib0014","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101026_bib0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.lungcan.2009.06.025","article-title":"Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy","volume":"68","author":"Tomizawa","year":"2010","journal-title":"Lung Cancer"},{"issue":"17","key":"10.1016\/j.ctarc.2025.101026_bib0016","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.ejca.2011.06.046","article-title":"Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment","volume":"47","author":"Becker","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101026_bib0017","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cllc.2012.01.006","article-title":"Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib","volume":"13","author":"Koizumi","year":"2012","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101026_bib0018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101026_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101026_bib0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:34:21Z","timestamp":1765485261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"alternative-id":["S2468294225001625"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101026","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101026"}}